Facilitating RP2D decisions for CAR T cell therapy clinical studies using a QSP model
Alexander V. Ratushny(Center for Infectious Disease Research), Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Steven L. Chang(Brigham and Women's Hospital), Lisa M. Kelly(Bristol-Myers Squibb (United States)), Allison Kaeding(Bristol-Myers Squibb (United States)), Yan Li(Hebei Medical University), Brian Schmidt(National Institutes of Health), Hongxiang Hu(Bristol-Myers Squibb (United States)), Yanping Chen(Bristol-Myers Squibb (United States)), Meng Li(University Hospital Magdeburg), Chris Davis, Akintunde Bello(Bristol-Myers Squibb (United States))
Cited by 0
Related Papers
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
|Cancer Cell|2021|624
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma
|Cancer Cell|2021|515
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505